SCHEMBL2068709

SCHEMBL2068709

CS(=O)(=O)Nc1[c]nccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.38
PTGS1 P23219 6/20 0.37
PTGS2 P35354 6/20 0.37
KIF11 P52732 1/20 0.37
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
KEAP1 Q14145 1/20 0.34
ADRA1A P35348 1/20 0.34
ABL1 P00519 1/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
GLO1 Q04760 2/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
ALOX15 P16050 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067493 0.80 KEAP1 (0.38) CYP17A1PTGS1PTGS2KEAP1ADRA1A
SCHEMBL2069881 0.75 PTGS1 (0.44) PTGS1PTGS2PIK3CDPIK3CAPIK3CB
SCHEMBL2068918 0.75
SCHEMBL2067557 0.73 PTGS1 (0.43) PTGS1PTGS2KEAP1HTTGLO1
SCHEMBL2067010 0.71 PTK2 (0.39) ABL1HTTGAAALOX15ALDH1A1
SCHEMBL558368 0.68
SCHEMBL2067604 0.67 GLO1 (0.41) PTGS1PTGS2KEAP1ADRA1AHPGD
SCHEMBL3877782 0.65 SMN1; SMN2 (0.37) PTGS1PTGS2HTTGLO1ALOX15
SCHEMBL2068369 0.64 PIK3CD (0.38) CYP17A1PTGS1PTGS2KIF11PIK3CD
SCHEMBL4984434 0.64 HTT (0.35) PIK3CDPIK3CAPIK3CBPIK3CGKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
WO-2010146351-A1 INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2010-12-23 WO disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CYP17A1 3178/4885PTGS1 1213/4885PTGS2 1610/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CYP17A1 3178/4885PTGS1 1213/4885PTGS2 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.